For the year ending 2025-12-31, CNTX had -$28,434,596 decrease in cash & cash equivalents over the period. -$26,419,328 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -36,123,615 |
| Research and development expense, acquired in process | 2,000,000 |
| Share-based compensation expense | 1,331,080 |
| Depreciation and amortization expense | 16,251 |
| Reduction in the carrying amount of operating lease right-of-use asset | 108,406 |
| Prepaid expenses and other current assets | -1,107,686 |
| Accounts payable | 1,095,967 |
| Accrued expenses and other current liabilities | 4,186,161 |
| Operating lease liability | -107,316 |
| Cash used in operating activities | -26,385,380 |
| Acquired in-process research and development | 2,000,000 |
| Purchase of property and equipment | 33,948 |
| Cash used in investing activities | -2,033,948 |
| Proceeds from the sale of common stock and prefunded warrants in private placement, net of offering costs | 0 |
| Payment of offering costs from the sale of common stock from atm facility | 15,268 |
| Proceeds from the sale of common stock from atm facility, net | 0 |
| Cash (used in) provided by financing activities | -15,268 |
| Net (decrease) increase in cash and cash equivalents | -28,434,596 |
| Cash and cash equivalents at beginning of period | 94,429,824 |
| Cash and cash equivalents at end of period | 65,995,228 |
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)